Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Other Non-Current Liabilities (2024 - 2025)

Maze Therapeutics has reported Other Non-Current Liabilities over the past 2 years, most recently at $1.1 million for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 12.9% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 12.9% year-over-year, with the annual reading at $1.1 million for FY2025, 12.9% up from the prior year.
  • Other Non-Current Liabilities was $1.1 million for Q4 2025 at Maze Therapeutics, roughly flat from $1.1 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $1.1 million in Q4 2025 and troughed at $969000.0 in Q4 2024.